The GLP-1 Update for Women in Midlife: What's Changed, What's New, and What's Next

If you had told me ten years ago that I'd be combining GLP-1 medications with hormone therapy to help my patients manage menopause-driven metabolic disease, I would have raised an eyebrow.

When I trained, we were taught that weight was simple math. Calories in minus calories out. Obesity was framed as a failure of willpower. Menopause weight gain? A vanity complaint.

I carried those biases into practice. For years, I told women to eat less and move more. I truly believed that was enough.

Then I watched, again and again, as women in midlife did everything right. They still gained weight, especially around the midsection. Their labs told a story of rising inflammation. They were high-stress, sleep-starved, and increasingly hopeless. It was no longer defensible to blame them. Menopause is a metabolic tipping point. The science is finally catching up.

What Are GLP-1 Medications and How Do They Work?

GLP-1s mimic a hormone naturally produced in your gut. They tell your brain you are full, slow gastric emptying, and improve how your body handles insulin and blood sugar. Modern agents like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce visceral fat stored around your organs, leading to better glucose control, improved lipid profiles, and reduced cardiometabolic risk.

Why Menopause Changes Weight, Fat Distribution, and Metabolism

During perimenopause and menopause, up to 70% of women gain weight. Estrogen loss drives fat into the abdomen. Visceral fat increases the risk of:

• Type 2 diabetes
• MASLD (metabolic dysfunction-associated steatotic liver disease)
• Cardiovascular disease

Estrogen loss also accelerates sarcopenia, the loss of lean muscle mass, which further slows metabolism. This process is biological, not psychological.

Can Hormone Therapy and GLP-1 Medications Work Better Together?

When I combined HT with GLP-1s in clinical practice, the results were significantly better than either alone. A 2024 study in Menopause confirmed it. Postmenopausal women on semaglutide plus HT lost significantly more weight at every checkpoint: 3, 6, 9, and 12 months, and were more likely to hit 5%, 10%, and 15% weight loss milestones while improving metabolic markers. HT likely enhances outcomes by improving sleep, mood, and motivation to stay active.

Can GLP-1 Medications Affect Hormone Therapy Absorption?

GLP-1 medications slow gastric emptying, which can reduce absorption of oral medications including oral estradiol, oral progestogens, and oral contraceptives. What this means in practice:

• If on a GLP-1 and oral estradiol, consider switching to transdermal estrogen (patch, gel, or spray) which bypasses the gut entirely
• If perimenopausal and using an oral contraceptive, consider backup contraception while on a GLP-1
• Oral micronized progesterone absorption may also be affected

What Is Retatrutide and Is It Safe for Menopausal Women Yet?

Retatrutide is a next-generation triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously. A 2023 Phase 2 trial in the NEJM showed 22.8% to 24.2% mean weight loss at 48 weeks. A 2024 trial in Nature Medicine showed liver fat reduction of 43% to 82% in 24 weeks in MASLD patients. Phase 3 TRIUMPH trials are ongoing.

Retatrutide is not FDA approved. The only legitimate access is through a clinical trial. Compounded retatrutide sold by telehealth platforms is not legal. Wait for FDA approval. Your impatience is not worth your health.

How to Minimize Side Effects and Maximize Comfort

GLP-1s can cause nausea, constipation, and appetite suppression. Most side effects are mild and improve with time. Here is what I advise:

• Hydration is non-negotiable. These drugs blunt thirst cues.
• Introduce fiber slowly. Gradual increases prevent bloating and constipation.
• Avoid carbonation. It worsens GI discomfort.
• Monitor your pace. Weight loss faster than 2 pounds per week raises risk for gallstones, muscle loss, and hair shedding.

Protecting Muscle Is Non-Negotiable

GLP-1s can unintentionally reduce protein intake. Muscle is medicine. My recommendations:

• Eat 1.3 to 1.6 grams of protein per kilogram of ideal body weight daily
• Resistance train 2 to 3 times per week
• Use a high-quality whey protein supplement
• Track progress with DEXA or a smart body composition scale

It Is Not Willpower. It Is Biology in a Broken Environment.

Obesity is not a moral failure. It is a biological response to an obesogenic environment. In the 1950s, fewer than 10% of Americans had obesity. Today, over 40% do. Sedentary jobs, ultra-processed food, endocrine disruptors, constant stress, poor sleep. This is not about discipline.

Final Thoughts: Rewriting the Narrative of Midlife Health

If you have been experiencing weight gain during menopause, it is not your fault. It is not a lack of willpower. And it is not too late. GLP-1 medications combined with hormone therapy offer a powerful, evidence-based approach. If your clinician lacks knowledge about these options, find one who does.

Protect your muscle. Prioritize your protein. Move your body. Advocate for yourself. Knowledge is freedom. Menopause is inevitable. Suffering is not.

References

1. Coskun T et al. LY3437943. Cell Metabolism. 2022.
2. Fisman EZ, Tenenbaum A. Tirzepatide. Cardiovascular Diabetology. 2021.
3. Giblin K et al. TRIUMPH trial rationale. Diabetes, Obesity and Metabolism. 2025.
4. Hurtado MD et al. Semaglutide in postmenopausal women. Menopause. 2024.
5. Jastreboff AM et al. Retatrutide Phase 2. NEJM. 2023.
6. Liu Q. GLP-1 receptor agonists. Frontiers in Endocrinology. 2024.
7. Rosenstock J et al. Retatrutide for T2D. The Lancet. 2023.
8. Sanyal AJ et al. Retatrutide for MASLD. Nature Medicine. 2024.
9. Tewari J et al. Retatrutide systematic review. Expert Review of Clinical Pharmacology. 2025.
10. Ushanova F, Demidova T. Menopause and incretin therapy. Women's Health and Reproduction. 2025.